| 1 |
34216511 | Successful withdrawal of erythropoiesis-stimulating agent after administration of an SGLT2 inhibitor, tofogliflozin, in people with diabetes. | 2022 Jan |
1 |
| 2 |
34617381 | Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. | 2022 Feb |
1 |
| 3 |
35123483 | Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial. | 2022 Feb 5 |
1 |
| 4 |
35367765 | Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. | 2022 May |
1 |
| 5 |
32597517 | Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). | 2021 Feb |
2 |
| 6 |
33377253 | A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin. | 2021 May |
2 |
| 7 |
33397376 | Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. | 2021 Jan 4 |
1 |
| 8 |
33769665 | Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. | 2021 Jul |
1 |
| 9 |
34357559 | The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. | 2021 Sep |
2 |
| 10 |
34388297 | Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors. | 2021 Nov |
1 |
| 11 |
34603858 | Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control. | 2021 Aug |
1 |
| 12 |
34843041 | The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria. | 2021 Nov 29 |
2 |
| 13 |
31608549 | Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. | 2020 Feb |
1 |
| 14 |
31979355 | Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. | 2020 Jan 23 |
2 |
| 15 |
32034997 | Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). | 2020 Jul |
1 |
| 16 |
32096571 | Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. | 2020 Aug |
3 |
| 17 |
32134370 | Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. | 2020 |
1 |
| 18 |
32231752 | Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus. | 2020 Mar |
1 |
| 19 |
32646498 | Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. | 2020 Jul 9 |
2 |
| 20 |
32707593 | Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor. | 2020 Sep |
3 |
| 21 |
32849941 | Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus. | 2020 Aug |
1 |
| 22 |
29766812 | Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. | 2019 |
3 |
| 23 |
30103216 | Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus. | 2019 Jun |
1 |
| 24 |
30627276 | Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes. | 2019 Jan |
2 |
| 25 |
30702214 | Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). | 2019 Sep |
1 |
| 26 |
30811541 | Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. | 2019 Sep 1 |
1 |
| 27 |
30835599 | An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. | 2019 May |
2 |
| 28 |
31033218 | Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. | 2019 Nov |
2 |
| 29 |
31210529 | Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor. | 2019 Jul |
1 |
| 30 |
31321581 | Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients. | 2019 Aug |
1 |
| 31 |
31325786 | Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. | 2019 Oct 15 |
1 |
| 32 |
28846182 | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. | 2018 Feb |
1 |
| 33 |
29032638 | Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline. | 2018 Jul |
1 |
| 34 |
29171930 | Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. | 2018 Apr |
2 |
| 35 |
29335890 | Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome: A Case Report. | 2018 Feb |
2 |
| 36 |
29507863 | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. | 2018 |
1 |
| 37 |
29660244 | Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated. | 2018 Aug |
1 |
| 38 |
29749099 | This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated". | 2018 Aug |
1 |
| 39 |
30145651 | Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy. | 2018 Oct |
1 |
| 40 |
30815551 | Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. | 2018 Apr |
1 |
| 41 |
28371205 | Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. | 2017 Oct |
2 |
| 42 |
28427104 | Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects. | 2017 Jun |
1 |
| 43 |
28864997 | Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. | 2017 Oct |
1 |
| 44 |
30279791 | Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy. | 2017 Jul |
1 |
| 45 |
30603323 | Evaluation of metabolic parameters and body composition in Japanese patients with type 2 diabetes mellitus who were administered tofogliflozin for 48 weeks. | 2017 Jun |
1 |
| 46 |
26158396 | Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation. | 2016 Mar |
1 |
| 47 |
26158794 | A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs. | 2016 Feb |
3 |
| 48 |
26871504 | Development of a Scalable Synthesis of Tofogliflozin. | 2016 Mar 4 |
2 |
| 49 |
27304784 | Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. | 2016 Aug 1 |
2 |
| 50 |
25805666 | Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. | 2015 Jul |
1 |